Drug Type Monoclonal antibody |
Synonyms SRK 373, SRK373 |
Target |
Action inhibitors |
Mechanism TGF-β1 inhibitors(Transforming growth factor beta 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fibrosis | Preclinical | United States | 01 Jan 2025 |